TrialAnnals of neurology2018

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.

Jerry S Wolinsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.